

How does the Chiasma OPTIMAL phase 3 trial differ or compare to the MPOWERED Phase 3 trial?

The CHIASMA OPTIMAL was a randomized, double-blind, placebo-controlled, nine-month comparison of MYCAPSSA and placebo looking at superiority of MYCAPSSA response over placebo after 36 weeks.

The MPOWERED trial is a randomized, open-label and active-controlled, 15-month trial intended to support approval in the EU. The endpoints are designed to assess sustained response on MYCAPSSA vs. SSA injections after 9 months (following a 6-month run-in).

Date: June 26, 2020